Datroway approved in the US for patients with previously treated metastatic HR-positive breast cancer
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Application based on results from the TROPION-Breast01 Phase III trial
Subscribe To Our Newsletter & Stay Updated